ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PLX vs PALI // PIOTROSKI F-SCORE QUALITY

Protalix BioTherapeutics Inc. (NYSE) VS. Palisade Bio Inc. (NASDAQ) • 15-METRIC TALLY: PLX 3 — PALI 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLX VS. PALI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PLX PALI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 48.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -13.00% -35.00% +22.00 PLX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.48% -5.23% -1.25 PALI /fcf-yield <GO>
Operating Margin -10.40% — — TIE /operating-margins <GO>
Net Profit Margin -12.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) -1.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.3 30.1 +17.17 PLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $210.3M $207.4M $2.9M PLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PLX REV PALI REV PLX GROSS % PALI GROSS % PLX FCF PALI FCF
FY 2025 $52.7M $0 48.8% — -$13.6M -$10.8M
FY 2024 $53.4M $0 54.5% — $7.4M -$12.2M
FY 2023 $65.5M $250.0K — — -$1.3M -$11.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLX // BETA —
PALI // BETA —